Evidence map›Paper›PMID 23688863›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2013

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

K Yeon Choi, B Sharon, H H Balfour, K Belani, T C Pozos, M R Schleiss

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Review
  5. [A 5-year retrospective clinical study of perinatal cytomegalovirus infection].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016
    Article
  6. Approach to drug-resistant cytomegalovirus in transplant recipients.Current opinion in infectious diseases · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

K Yeon ChoiDivision of Pediatric Infectious Diseases and Immunology, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
B Sharon
H H Balfour
K Belani
T C Pozos
M R Schleiss
University of Minnesota Medical Center · USChildren’s Minnesota - St. Paul Hospital · US

Funding

Viral Immunomodulation and Rational CMV Vaccine DesignR01HD044864 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI GEBALLE, ADAM P., MCVOY, MICHAEL A · 2003 to 2015
$4.5M
Bedside-to-Bench Research Training for Pediatric Infectious Diseases FellowsT32HD068229 · NICHD · UNIVERSITY OF MINNESOTA · PI SCHLEISS, MARK R. · 2011 to 2015
$650k
NICHD NIH HHS HD044064NICHD NIH HHS R01 HD044864NICHD NIH HHS T32 HD068229PHS HHS 038416
6 · The paper itself

Abstract

Congenital infection with human cytomegalovirus (CMV) is a major cause of morbidity, including sensorineural hearing loss (SNHL), in newborns. Antiviral therapy with ganciclovir (GCV) and its oral prodrug, valganciclovir (VAL-GCV) are increasingly being administered to infected infants, toward the goal of improving neurodevelopmental and auditory outcomes. In this case report, we describe a symptomatic congenitally infected infant treated with VAL-GCV in whom GCV resistance was suspected, based on a 50-fold increase in viral load after 6 weeks of oral therapy. Analyses of CMV sequences from both blood and urine demonstrated populations of viruses with M460V and L595F mutations in the UL97 phosphotransferase gene. In contrast, analysis of viral DNA retrieved from the newborn dried blood spot demonstrated wild-type UL97 sequences. DNAemia resolved after the discontinuation of VAL-GCV. Long-term VAL-GCV therapy in congenitally infected infants can select for resistant viral variants, and anticipatory virological monitoring may be warranted.

Indexed as

AdultAntiviral AgentsCytomegalovirusCytomegalovirus InfectionsDrug Resistance, ViralFemaleGanciclovirHumansInfant, NewbornMalePregnancyValganciclovirAntiviral AgentsGanciclovirValganciclovir

Identifiers

PMID23688863
PMCPMC3807863
OpenAlexW2001006318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.